LC-MS/MS-based approach for obtaining exposure estimates of metabolites in early clinical trials using radioactive metabolites as reference standards.
An LC-MS/MS-based approach that employs authentic radioactive metabolites as reference standards was developed to estimate metabolite exposures in early drug development studies. This method is useful to estimate metabolite levels in studies done with non-radiolabeled compounds where metabolite standards are not available to allow standard LC-MS/MS assay development. A metabolite mixture obtained from an in vivo source treated with a radiolabeled compound was partially purified, quantified, and spiked into human plasma to provide metabolite standard curves. Metabolites were analyzed by LC-MS/MS using the specific mass transitions and an internal standard. The metabolite concentrations determined by this approach were found to be comparable to those determined by valid LC-MS/MS assays. This approach does not requires synthesis of authentic metabolites or the knowledge of exact structures of metabolites, and therefore should provide a useful method to obtain early estimates of circulating metabolites in early clinical or toxicological studies.
Pharmaceutical Candidate Optimization, Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, USA. donglu.zhang@bms.com
Donglu
D
Zhang
Nirmala
N
Raghavan
Theodore
T
Chando
Janice
J
Gambardella
Yunlin
Y
Fu
Duxi
D
Zhang
Steve E
SE
Unger
W Griffith
WG
Humphreys
D000818:Animals; D002853:Chromatography, Liquid / Q000379:methods*; D017321:Clinical Trials, Phase I as Topic; D004285:Dogs; D020719:Glucuronides / Q000378:metabolism; D006801:Humans; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D011868:Radioisotopes; D012015:Reference Standards; D053719:Tandem Mass Spectrometry / Q000379:methods*
D020719:Glucuronides; D004364:Pharmaceutical Preparations; D011868:Radioisotopes